computer-generated, stratified, block-randomization schedule (AstraZeneca ltd)
90
Structured Review
AstraZeneca ltd
computer-generated, stratified, block-randomization schedule
Computer Generated, Stratified, Block Randomization Schedule, supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/computer-generated%2C+stratified%2C+block-randomization+schedule/computer+generated+randomization+scheme/pmc05106000__pone__0166125__s006-852-16-27
Average 90 stars, based on 1 article reviews
Computer Generated, Stratified, Block Randomization Schedule, supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/computer-generated%2C+stratified%2C+block-randomization+schedule/computer+generated+randomization+scheme/pmc05106000__pone__0166125__s006-852-16-27
Average 90 stars, based on 1 article reviews
computer-generated, stratified, block-randomization schedule - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Sequencing:Article Title: Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Article Snippet: Results: 800 patients were analyzed.. After 24 weeks, mean hemoglobin A1c decreased by 0.79% to 0.96% with dapagliflozin compared with 0.39% with placebo (mean difference, 0.40% [95% CI, 0.54% to 0.25%] in the 2.5-mg group, 0.49% [CI, 0.65% to 0.34%] in the 5-mg group, and 0.57% [CI, 0.72% to 0.42%] in the 10-mg group).. Daily insulin dose decreased by 0.63 to 1.95 U with dapagliflozin and increased by 5.65 U with placebo (mean difference, 7.60 U [CI, 10.32 to 4.87 U] in the 2.5-mg group, 6.28 U [CI, 8.99 to 3.58 U] in the 5-mg group, and 6.82 U [CI, 9.56 to 4.09 U] in the 10-mg group). Article Title: Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis Article Snippet: Bias Authors' judgement Support for Selection:Article Title: Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Article Snippet: Results: 800 patients were analyzed.. After 24 weeks, mean hemoglobin A1c decreased by 0.79% to 0.96% with dapagliflozin compared with 0.39% with placebo (mean difference, 0.40% [95% CI, 0.54% to 0.25%] in the 2.5-mg group, 0.49% [CI, 0.65% to 0.34%] in the 5-mg group, and 0.57% [CI, 0.72% to 0.42%] in the 10-mg group).. Daily insulin dose decreased by 0.63 to 1.95 U with dapagliflozin and increased by 5.65 U with placebo (mean difference, 7.60 U [CI, 10.32 to 4.87 U] in the 2.5-mg group, 6.28 U [CI, 8.99 to 3.58 U] in the 5-mg group, and 6.82 U [CI, 9.56 to 4.09 U] in the 10-mg group). Article Title: Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis Article Snippet: Bias Authors' judgement Support for Blocking Assay:Article Title: Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Article Snippet: Results: 800 patients were analyzed.. After 24 weeks, mean hemoglobin A1c decreased by 0.79% to 0.96% with dapagliflozin compared with 0.39% with placebo (mean difference, 0.40% [95% CI, 0.54% to 0.25%] in the 2.5-mg group, 0.49% [CI, 0.65% to 0.34%] in the 5-mg group, and 0.57% [CI, 0.72% to 0.42%] in the 10-mg group).. Daily insulin dose decreased by 0.63 to 1.95 U with dapagliflozin and increased by 5.65 U with placebo (mean difference, 7.60 U [CI, 10.32 to 4.87 U] in the 2.5-mg group, 6.28 U [CI, 8.99 to 3.58 U] in the 5-mg group, and 6.82 U [CI, 9.56 to 4.09 U] in the 10-mg group). Article Title: Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis Article Snippet: Bias Authors' judgement Support for |